Announcements Trials
Browse Landscape

Phase

Phase 3 7Phase 2 3Phase 1/2 2Phase 2/3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Urinary Bladder Neoplasms 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms 1Myelodysplastic Syndromes 1Mesothelioma 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphohistiocytosis, Hemophagocytic 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Breast Neoplasms 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Has announcements × Leukemia × Clear all
NCT04145531 2023-11-18

An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL)

Jazz Pharmaceuticals

Phase 2/3 Completed
229 enrolled 17 charts 2 FDA
LymphoidOther hematologic neoplasm

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡